Fishing for New Drugs
Author:
- 1 November 2005
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (31) , 7780-7782
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor BiologyJournal of Clinical Oncology, 2005
- JNK activation is critical for Aplidin™-induced apoptosisOncogene, 2004
- In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical developmentLeukemia, 2003
- Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4Leukemia, 2003
- Structure−Activity Relationships of the DidemninsJournal of Medicinal Chemistry, 1996
- A Phase II Trial of Didemnin B (NSC #335319) in Patients with Previously Treated Epithelial Ovarian Cancer A Gynecologic Oncology Group StudyAmerican Journal of Clinical Oncology, 1993
- Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidneyInvestigational New Drugs, 1992
- Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptideEuropean Journal of Cancer and Clinical Oncology, 1988
- Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean TunicateScience, 1981